Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Assets: 2019-2024

Historic Assets for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $560.4 million.

  • 4D Molecular Therapeutics' Assets fell 29.81% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $424.0 million, marking a year-over-year decrease of 29.81%. This contributed to the annual value of $560.4 million for FY2024, which is 64.87% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Assets stood at $560.4 million, which was up 64.87% from $339.9 million recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Assets high stood at $560.4 million for FY2024, and its period low was $261.8 million during FY2022.
  • For the 3-year period, 4D Molecular Therapeutics' Assets averaged around $387.4 million, with its median value being $339.9 million (2023).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Assets surged by 395.12% in 2020 and then decreased by 25.92% in 2022.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Assets stood at $288.3 million in 2020, then climbed by 22.60% to $353.5 million in 2021, then dropped by 25.92% to $261.8 million in 2022, then rose by 29.81% to $339.9 million in 2023, then soared by 64.87% to $560.4 million in 2024.